Last reviewed · How we verify

Ahmed Hassan Nouh MD — Portfolio Competitive Intelligence Brief

Ahmed Hassan Nouh MD pipeline: 1 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Bimatoprost 0.03% solution Bimatoprost 0.03% solution marketed Prostaglandin F analog Prostaglandin F receptor (FP receptor) Ophthalmology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. AbbVie · 1 shared drug class
  2. Allergan · 1 shared drug class
  3. Association for Innovation and Biomedical Research on Light and Image · 1 shared drug class
  4. CHU de Quebec-Universite Laval · 1 shared drug class
  5. Dr. David Yan · 1 shared drug class
  6. Kasr El Aini Hospital · 1 shared drug class
  7. Merck Sharp & Dohme LLC · 1 shared drug class
  8. Pfizer's Upjohn has merged with Mylan to form Viatris Inc. · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Ahmed Hassan Nouh MD:

Cite this brief

Drug Landscape (2026). Ahmed Hassan Nouh MD — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/ahmed-hassan-nouh-md. Accessed 2026-05-17.

Related